Clinical characteristics
| Statin group (n = 186) | No statin group (n = 314) | p Value | |
|---|---|---|---|
| Data are presented as the mean value (SD) or number (%) of patients. | |||
| ACE, angiotensin converting enzyme; CCS, Canadian Cardiovascular Society; HDL, high density lipoprotein; LDL, low density lipoprotein; NS, not significant | |||
| Men (%) | 144 (77%) | 243 (77%) | NS |
| Age (years) | 61 (11) | 62 (11) | NS |
| Body mass index (kg/m2) | 27 (3) | 27 (4) | NS |
| Mean blood pressure (mm Hg) | 93 (13) | 96 (16) | 0.04 |
| Heart rate (beats per minute) | 69 (11) | 73 (12) | 0.008 |
| Left ventricular ejection fraction (%) | 66 (10) | 65 (12) | NS |
| Left ventricular end diastolic pressure (mm Hg) | 13 (6) | 14 (6) | NS |
| Central venous pressure (mm Hg) | 6 (3) | 5 (2) | NS |
| Duration of angina pectoris (months) | 28 (47) | 19 (42) | 0.02 |
| Severity of angina pectoris (CCS class) | 1.5 (1.2) | 1.5 (1.1) | NS |
| Cardiovascular risk factors | |||
| Diabetes mellitus | 26 (14%) | 53 (17%) | NS |
| Systemic hypertension | 96 (52%) | 159 (51%) | NS |
| Smoking | 78 (42%) | 134 (43%) | NS |
| Obesity | 41 (22%) | 71 (23%) | NS |
| Hypercholesterolaemia | 156 (84%) | 98 (31%) | <0.0001 |
| Family history of coronary artery disease | 60 (32%) | 112 (36%) | NS |
| Cardiovascular medication | |||
| Aspirin | 159 (85%) | 259 (82%) | NS |
| β Blockers | 131 (70%) | 179 (57%) | 0.003 |
| Nitrates | 77 (41%) | 119 (38%) | NS |
| ACE inhibitors | 51 (27%) | 82 (26%) | NS |
| Calcium antagonists | 36 (19%) | 63 (20%) | NS |
| Diuretics | 29 (16%) | 36 (12%) | NS |
| Serum lipids | |||
| Cholesterol (mmol/l) | 5.4 (1.3) | 5.6 (1.1) | 0.01 |
| HDL cholesterol (mmol/l) | 1.2 (0.3) | 1.2 (0.3) | NS |
| LDL cholesterol (mmol/l) | 3.3 (1.1) | 3.5 (1.0) | 0.02 |
| Total cholesterol/HDL cholesterol | 4.7 (1.6) | 5.1 (1.9) | 0.02 |
| Triglycerides (mmol/l) | 2.3 (1.9) | 2.1 (1.5) | NS |